首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 46 毫秒
1.
目的:分析新活素前置应用对急性心肌梗死急诊经皮冠脉介入术(PCI)术后病人心功能、氨基末端脑利钠肽前体(NT-ProBNP)水平、心肌微循环及心脏不良事件发生的影响。方法:选取2020-2021年住院治疗的急性心肌梗死88例病人作为研究对象,随机分为观察组43例和对照组45例,所有病人入院后均行急诊PCI手术治疗,观察组病人确诊后在规范药物治疗的基础上立即启动新活素治疗,对照组不应用新活素治疗。比较2组病人的心功能、NT-ProBNP水平、心肌微循环以及不良事件发生情况。结果:观察组心功能优于对照组,其左心室射血分数高于对照组,左心室舒张末期容积、左心室舒张末期内径低于对照组(P<0.01);观察组NT-ProBNP水平低于对照组(P<0.01);观察组心肌梗死溶栓血流分级高于对照组(P<0.01)、计帧值低于对照组(P<0.01);观察组发生心肌梗死、恶性心律失常、心力衰竭、心源性猝死等不良事件发生率低于对照组(P<0.05)。结论:急性心肌梗死急诊PCI病人前置使用新活素进行治疗,可显著改善心功能,降低NT-ProBNP水平,改善心肌微循环,降低心脏不...  相似文献   

2.
目的:探讨早期重组人脑利钠肽(Rh BNP)治疗老年急性心肌梗死患者经皮冠状动脉介入(PCI)治疗后心功能不全的临床效果。方法:76例行PCI的急性心肌梗死并术后心功能不全者分为对照组(抗心衰治疗)和观察组(在常规治疗的基础上早期予Rh BNP),10 d后通过心功能Killip分级评定、超声心动图检测左室射血分数(LVEF)及左室舒张末径(LVDd)等,比较两组心功能改善情况。结果:观察组用药后心功能改善总有效率84.2%,对照组52.6%(P<0.05);观察组LVEF较对照组增加(P<0.05),LVDd较对照组明显缩小(P<0.05);观察组24 h尿量增多(P<0.05),血电解质紊乱发生率降低(P<0.05),强心药物使用天数(P<0.05)减少。结论:早期使用Rh BNP可明显改善PCI术后合并心功能不全的老年急性心肌梗死者心功能。  相似文献   

3.
谢江  张健  王显 《华中医学杂志》2007,31(4):276-277
目的 观察合并慢性肾功能不全的急性心肌梗死患者经皮冠状动脉介入治疗术(PCI)后长期服用曲美他嗪的有效性和安全性.方法 合并慢性肾功能不全的初发急性心肌梗死患者40例,PCI术后随机分为2组,2组年龄、性别、合并病变、肾功能及心功能分级均相仿.对照组(30例)PCI术后不服用曲美他嗪;治疗组(30例)PCI术后口服曲美他嗪治疗12个月.各组其他冠心病二级预防药物均相同.观察2组患者24 h尿蛋白定量、肌酐清除率和超声心动图变化.结果 与对照组相比,曲美他嗪治疗组肾功能未见恶化(P<0.05),24 h尿蛋白定量未增加,而心功能恢复较好(P<0.05).结论 合并慢性肾功能不全的急性心肌梗死患者PCI术后长期服用曲美他嗪安全有效.  相似文献   

4.
目的 探讨IABP治疗急性心肌梗死合并心功能不全的护理体会方法 选择急性心肌梗死合并心功能不全的100例患者,所有患者均行IABP治疗,对照组术后给予常规护理,观察组实施针对性的护理干预.观察两组患者治疗后不良反应发生率,比较治疗前后焦虑(SAS)、抑郁(SDS)评分,并记录护理满意度.结果 治疗后,观察组不良反应发生率明显比对照组低[10.00%(5/50)vs 48.00%(24/50)],两组间比较差异具有统计学意义(P<0.05);治疗后,观察组SAS、SDS评分均比对照组低[(30.01±5.87)vs(41.34±7.11),(29.03±5.42)vs(40.87±7.43)],两组间比较差异具有统计学意义(P<0.05);观察组护理满意度比对照组高[98.0%(49/50)vs 90.0%(45/50)],但差异无统计学意义.结论 在急性心肌梗死合并心功能不全患者给予IABP的治疗过程中实施针对性的护理干预措施,可有效降低不良反应的发生率,在帮助病情恢复上具有积极意义,值得进行临床推广应用.  相似文献   

5.
目的探讨主动脉内球囊反搏(IABP)在急性心肌梗死(AMI)并泵衰竭患者经皮冠状动脉介入(PCI)治疗的临床疗效。方法观察组35例急性心肌梗死并泵衰竭患者在IABP辅助下行冠脉造影及PCI术。对照组24例AMI并泵衰竭患者仅使用常规药物及PCI术。观察组PCI术前或术后置入IABP球囊。结果观察组使用IABP后低血压或休克状况明显好转、尿量明显增多、心率明显减慢30例(85.71%),死亡5例(14.29%)。对照组24例中,患者血液动力学得以改善并接受PCI术17例(70.83%),死亡7例(29.17%)。两组疗效比较有显著性差异(P<0.01)。结论IABP辅助治疗下介入治疗急性心肌梗死并泵衰竭患者,可明显降低其心源性死亡率,改善生存率。  相似文献   

6.
目的 分析主动脉内球囊反搏(IABP)应用时机对急性心肌梗死(AMI)合并心源性休克(CS)经皮冠状动脉治疗(PCI)术患者血流动力学及心肌损伤标志物的影响。方法 采用前瞻性研究方式,选取2017年7月至2022年1月于南阳南石医院行PCI治疗的60例AMI合并CS患者为研究对象,按随机数表法将其分为术前组(30例)、术后组(30例),两组均于入院后行常规PCI手术,术前组在PCI手术开始前置入IABP,术后组于PCI手术结束后1 h内置入IABP。比较两组患者手术前后临床指标(心脏指数、心率、尿量)、血流动力学指标[肺动脉楔压(PCWP)、有创平均动脉压(MABP)、有创动脉收缩压(SBP)]、心肌损伤标志物[肌酸激酶同工酶(CK-MB)、心脏型脂肪酸结合蛋白(H-FABP)、肌钙蛋白I(cTnI)]、术后30 d病死率。结果 治疗后,两组心率、尿量均有改善,且术前组心率低于术后组,尿量高于术后组(P<0.05)。治疗后,两组PCWP、MABP、SBP均有改善,且术前组PCWP低于术后组,MABP、SBP高于术后组(P<0.05)。治疗后,两组CK-MB、H-FABP、c...  相似文献   

7.
 【目的】探讨在合并左室收缩功能不全慢性闭塞病变(chronic total occlusion, CTO)病变PCI(percuteneous coronary intervention)过程中主动脉内球囊反搏 (Intra aortic balloon pulsation,IABP)预处理的临床意义。【方法】回顾性分析2004年到2011年南京市第一医院心内科,因合并左室收缩功能不全CTO患者而行PCI及IABP治疗的患者63例,按照IABP置入时间分组为PCI术前IABP预处理组和PCI术后IABP组。记录两组患者的基线临床资料,比较两组患者术中靶病变成功血运重建率,无复流发生率,PCI相关心肌梗死发生率,术后一年内全因死亡率。【结果】两组的靶病变血运重建率IABP预处理组为75.2%,术后IABP组为63.2%(P>0.05);IABP预处理组无复流发生率为16.3%,术后IABP组无复流发生率为42.1%(P<0.05);PCI相关心肌梗死发生率IABP预处理组为75.6%,术后IABP组为52.6%(P<0.05);术后一年内全因死亡率分别为:IABP预处理组为18.6%,术后IABP组为31.6%(P>0.05)。【结论】在合并左室收缩功能不全CTO病变介入治疗中,IABP预处理较术后IABP能显著减少术中无复流发生率,显著减轻术后PCI相关心肌梗死发生率,对靶病变血运重建率无显著影响,对一年内全因死亡率无显著影响。  相似文献   

8.
目的 探讨主动脉内球囊反搏(IABP)置入时机对高危经皮冠状动脉介入(HR-PCI)术患者近期(术后30 d)预后的影响。方法 回顾性分析80例行IABP辅助治疗的HR-PCI患者的临床资料,根据IABP置入时机将患者分为A组[经皮冠状动脉介入(PCI)术前置入组]46例和B组(PCI术后置入组)34例。比较两组合并疾病、冠心病类型、冠脉病变部位及合并心源性休克、室性心律失常、急性心肌梗死机械并发症发生情况、药物使用情况、支架置入个数、无复流率、IABP辅助时间、IABP相关并发症发生情况及近期病死率等,分析IABP置入时机对HR-PCI术患者近期预后的影响。结果 A组左前降支和左主干病变、急性ST段抬高型心肌梗死、合并心源性休克的比例及血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂使用比例高于B组,β受体阻滞剂使用率、IABP辅助时间、再次PCI率、院内病死率及术后30 d病死率均低于或短于B组(均P<0.05)。多因素Logistic回归分析结果显示,PCI术后置入IABP是HR-PCI术患者术后30 d死亡的危险因素(P<0.05)。结论 与PCI术后置入IABP相比,PCI术前置...  相似文献   

9.
目的探讨急性心肌梗死(AMI)患者通过经皮冠脉介入术(PCI)进行早期再灌注后其血中B型钠利尿肽(BNP)的动态变化及对心室重塑的影响。方法将2007年9月~2012年9月入住我院的100例急性心肌梗死患者按照抽签法随机地均分为对照组与观察组,对照组给予药物保守治疗,观察组给予PCI治疗,比较两组治疗前后血瘀证积分值、BNP、CPK、CK-MB与心功能指标变化情况等。结果两组治疗前后血瘀证积分差异均具有统计学意义(P<0.05,P<0.01),且观察组治疗后与对照组相比,差异具有高度统计学意义(P<0.01),且两组治疗前后差值相比,差异也具有高度统计学意义(P<0.01);两组治疗后BNP、CPK、CK-MB与心功能指标值差异具有统计学意义(P<0.05,P<0.01)。结论 PCI可以隆低AMI患者血中BNP含量,从而改善患者的左室功能以及左室重塑。  相似文献   

10.
目的探讨急性心肌梗死PCI术前应用盐酸替罗非班对患者心肌坏死标记物的影响。方法 92例急性心肌梗死行急诊PCI术的病人中48例入院确诊为急性心肌梗死后立即给予盐酸替罗非班后行急诊PCI设为治疗组;44例术前不给盐酸替罗非班仅行急诊PCI术作为对照组。两组术前均嚼服阿司匹林片300mg,硫酸氢氯吡格雷片600mg,两组患者术前、术后24h分别检测磷酸肌酸激酶同工酶(CK-MB)、肌钙蛋白T(cTnT)。结果术后24h两组心肌梗死标记物与术前相比明显升高(P〈0.05);术后24h对照组与治疗组相比心肌梗死标记物有明显差异(P〈0.05)。结论早期应用盐酸替罗非班可减轻心肌的坏死。  相似文献   

11.
磁共振心肌灌注成像评价心肌梗死PTCA治疗前后心肌存活   总被引:1,自引:0,他引:1  
目的 评价磁共振心肌灌注成像(MRMPI) 检测心肌梗死存活心肌的作用. 方法 选择心肌梗死患者51 例.采用1.5 T MR扫描仪,反转恢复快速小角度激励( IR-turbo FLASH) 序列,全部患者均在静脉注射钆喷替酸葡甲胺(Gd-DTPA) 0.1 mmol/kg、MRMPI 首过期及5~30 min 延迟期成像.21 例行静息、负荷99锝单光子发射计算机体层摄影术( single photon emission computed tomography, SPECT) 进行对照研究.首过期行短轴面成像,延迟期行短轴面及长轴面成像.结果 51例心肌梗死患者,42 例(82.3%) 首过期显示灌注减低;50 例(98%) 延迟增强.在21例168个心肌段SPECT诊断无活性心肌段48个,MRMPI 示梗死区均有延迟增强,SPECT诊断存活心肌段120 个,MRMPI 示97段无延迟增强.以静息、负荷99m锝SPECT 作为参考标准,MRMPI 的敏感度、特异度分别为100%、80.8%. 结论 MRMPI 可有效地检测心肌梗死的存活和非存活心肌,以及其程度和范围.  相似文献   

12.
《中华医学杂志(英文版)》2012,125(19):3589-3590
Myocardial bridge (MB) is regarded as a common anatomic variant rather than a congenital condition anomaly,defined as the intramyocardial course of a portion of the coronary artery.It was first mentioned by Rayman in 1737 and first described by Grainicianu in the early 1920s.The current gold standard for diagnosing  相似文献   

13.
The myocardial viability after myocardial infarction was evaluated by intravenous myocardial contrast echocardiography. Intravenous real-time myocardial contrast echocardiography was performed on 18 patients with myocardial infarction before coronary revascularization. Follow-up echocardiography was performed 3 months after coronary revascularization. Segmental wall motion was assessed using 18-segment LV model and classified as normal, hypokinesis, akinesis and dyskinesis. Viable myocardium was defined by evident improvement of segmental wall motion 3 months after coronary revascularization. Myocardial perfusion was assessed by visual interpretation and divided into 3 conditions: homogeneous opacification; partial or reduced opaciflcation or subendocardial contrast defect; contrast defect. The former two conditions were used as the standard to define the viable myocardium. The results showed that 109 abnormal wall motion segments were detected among 18 patients with myocardial infarction, including 47 segments of hypokinesis, 56 segments of akinesis and 6 segments of dyskinesis. The wall motion of 2 segments with hypokinesis before coronary revascularization which showed homogeneous opacification, 14 of 24 segments with hypokinese and 20 of 24 segments with akinese before coronary revascularization which showed partial or reduced opaciflcation or subendocardial contrast defect was improved 3 months after coronary revascularization. In our study, the sensitivity and specificity of evaluation of myocardial viability after myocardial infarction by intravenous real-time myocardial contrast echocardiography were 94.7% and 78.9%, respectively. It was concluded that intravenous real-time myocardial contrast echocardiography could accurately evaluate myocardial viability after myocardial infarction.  相似文献   

14.
Primary coronary revascularization by means of percutaneous coronary intervention(PCI)is a highly effective treatment of acute myocardial infarction re-establishing coronary perfusion and stopping the ongoing necrosis in the dependent myocardium.Single-photon emission computed tomography(SPECT)is the most widely used modality assessing myocardial salvage as the difference between the acute perfusion defect before intervention and the remaining scar size measured in a second scan several days after the event.SPECT allows quantification of area at risk(AAR)and final infarct size(FIS)by tracer injection prior to revascularization and after 1 month,respectively.SPECT provides the most validated measure of myocardial salvage and has been utilized in multiple randomizedclinical trials.However,SPECT is logistically challenging,expensive,and includes radiation exposure.More recently,a large number of studies have suggested that cardiac magnetic resonance(CMR)can determine salvage in a single examination by combining measures of myocardial oedema in the AAR exposed to ischaemia reperfusion with FIS quantification by late gadolinium enhancement.  相似文献   

15.
目的:通过心肌声学造影(MCE)对急性心梗经皮冠状动脉支架术(PCI)后心肌灌注的情况进行判断,了解其对左心功能及左室重构的影响.方法:采用病例对照的研究方法,根据PCI术后1周的MCE检查,将急性心梗患者分为灌注正常组、灌注稀疏组和灌注缺失组,并随访检查3个月、6个月的左室射血分数(LVEF)及左室舒张末内径(LVDd)的变化情况,比较组内及组间不同时段LVEF与LVDd的变化.结果:PCI术后3个月灌注稀疏组LVEF恢复到正常;灌注缺损组PCI术后LVEF的平均水平随时间变化而逐渐降低;灌注缺损组患者的LVEF低于灌注稀疏组和灌注正常组(P<0.05);术后6个月灌注缺损组LVDd平均水平高于灌注正常组和灌注稀疏组(P<0.05),灌注缺损组随时间的变化左室内径逐渐增大(P<0.05).结论:急性心梗患者PCI术后心肌微循环较差时,其左室射血分数降低,左室内径增大;MCE有利于对急性心梗患者PCI术后左心功能及左室重构评估.  相似文献   

16.
目的:观察水飞蓟素对心肌梗死小鼠的血流动力学、梗死面积及梗死边缘区凋亡蛋白表达情况。方法:将60只小鼠随机分为心肌梗死组、假手术组、心肌梗死+水飞蓟素组和心肌梗死溶剂组。建模成功4周后检测小鼠血流动力学变化,进行心脏超声检查,评价梗死面积、细胞凋亡指数以及凋亡蛋白Bcl-2、Bax、Cleaved-Caspase3的表达。结果:与心肌梗死组小鼠相比,水飞蓟素可显著减轻心肌梗死,改善心梗小鼠心功能,降低心肌细胞凋亡指数,增强Bcl-2蛋白表达和减弱Bax和Cleaved-Caspase3蛋白表达。结论:水飞蓟素能够减轻心肌梗死,改善心梗小鼠心室收缩功能,保护心肌,减少心肌细胞的凋亡,其机制与升高Bcl-2蛋白、降低Bax和Cleaved-Caspase3蛋白表达水平有关。  相似文献   

17.
目的:建立大鼠“肾阳虚证”下心肌梗死模型,探讨其与单纯心肌梗死模型大鼠在心肌形态学、心肌酶学及血液流变学方面的差异,为评价治疗胸痹心痛中药的药效学提供理论依据。方法:60只Wistar大鼠随机分为空白对照组、肾阳虚模型组、心肌梗死假手术组、单纯心肌梗死模型组及“肾阳虚证”下心肌梗死模型组,每组12只。在大鼠 “肾阳虚”情况下复制急性心肌梗死模型,测定各组大鼠心肌梗死面积 (MIS),血清天门冬氨酸氨基转化酶(AST)、肌酸磷酸激酶(CK)及乳酸脱氢酶(LDH)活性,同时测定血小板黏附率(PAR)、血小板聚集率(PAG)、红细胞沉降率(ESR)、红细胞压积(HCT)、体外血栓长度、血栓干重与湿重以及血栓弹力图等参数。结果: 大鼠“肾阳虚证”下心肌梗死模型与单纯心肌梗死模型在MIS,血清AST、CK及LDH活性,PAR、PAG、ESR及HCT增加程度差异无统计学意义(P>0.05);肾阳虚模型组、单纯心肌梗死模型组及“肾阳虚证”下心肌梗死模型组大鼠体外血栓干重及长度均明显增加(P<0.05或P<0.01),“肾阳虚证”下心肌梗死模型组的增加程度大于单纯心肌梗死模型组及肾阳虚模型组,但三者之间差异无统计学意义(P>0.05);尽管“肾阳虚证”下心肌梗死模型组大鼠血栓弹力图r、k值的缩短程度及ma值的增大程度高于单纯心肌梗死模型组,但2组之间差异无统计学意义(P>0.05)。结论:大鼠“肾阳虚证”下心肌梗死模型与单纯心肌梗死模型心肌梗死面积、血清心肌酶学、红细胞压积、血沉、血小板功能、体外血栓重量及血栓弹力图等指标均无明显差异。  相似文献   

18.
目的:探讨超声心肌造影技术在心肌梗塞(简称心梗)患者心肌微循环灌注改变中的应用价值。方法:对30例急性心梗患者进行超声心动图及心肌造影检查,观察患者梗塞区域(AMI组,同时以患者非梗塞区域为自身对照组)心肌微循环灌注并以CPS造影软件进行分析。结果:心肌梗塞患者梗塞区域心肌微循环灌注开始时间(AT)、达峰时间(APT)较同一切面内的非梗塞区域明显延长(P<0.05),梗塞区域造影剂灌注的峰值强度(PI)及灌注速度(β)均明显低于同一切面内的非梗塞区域(P<0.05)。结论:超声心肌造影技术可以定量评价心梗患者心肌微循环灌注,具有重要的临床应用价值。  相似文献   

19.
Background Small case series have suggested an association of coronary myocardial bridge (MB) with myocardial infarction (MI).However,the relationship between MB and major adverse cardiac events (MACE) remains largely unknown.The aim of this study was to assess the relationship between MB and MACE involving MI.Methods We performed a systematic search of MEDLINE,PreMEDLINE,and all EMB Reviews as well as a reference list of relevant articles according to the SPICO (Study design,Patient,Intervention,Control-intervention,and Outcome) criteria using the following keywords:myocardial bridging,myocardial bridge,intramural coronary artery,mural coronary artery,tunneled coronary artery,coronary artery overbridging,etc.Bibliographies of the retrieved publications were additionally hand searched.Studies were included for the meta-analysis if they satisfied the following criteria:(1) they evaluate the association of MB with cardiovascular endpoint event; (2) they included individuals with MB and those without MB; 3) they excluded individuals with obstructive coronary artery disease (CAD).Studies were reviewed by a predetermined protocol including quality assessment.Dates were pooled using a random effect model.Results Seven observational studies that followed 5 486 patients eligible for the enrolled criteria were included from 7 136 initially identified articles.The prevalence of MB was 24.8% (1 363/5 486).During 0.5-7.0 years of follow-up of this cohort of population,crude outcome rates were 8.0% in the MB group and 7.7% in the non-MB group.The odds ratio of overall MACE and MI were 1.34 (95% confidence interval (CI):0.57-3.17,P=0.51,n=7 studies) and 2.75 (95% CI:1.08-7.02,P <0.03,n=5 studies) respectively for subjects of MB compared to non-MB.Conclusion Relationship between MB and MI appears to be a real one,although the study did not reveal a connection of MB to MACE,suggesting whether the necessity of antiplatelet therapy needs to be further studied in a larger cohort of patients with MB prospectively.  相似文献   

20.

Background  Myocardial tissue-level perfusion failure is associated with adverse outcomes following ST-elevation myocardial infarction (STEMI) despite successful epicardial recanalization. We have developed a new quantitative index—thrombolysis in myocardial infarction (TIMI) myocardial perfusion frame count (TMPFC)—for assessing myocardial tissue level perfusion. However, factors affecting this novel index of myocardial perfusion are currently unknown.

Methods  A total of 255 consecutive STEMI patients undergoing primary angioplasty were enrolled. Myocardial tissue level perfusion was assessed by TMPFC, which measures the filling and clearance of contrast in the myocardium using cine-angiographic frame counting. We differentiate three groups with two cut off values for TMPFC: a TMPFC of 90 frames was the upper boundary of the 95% confidence interval (CI) for the TMPFC observed in normal arteries, and a TMPFC of 130 was the 75th percentile of TMPFC.

Results  STEMI patients with TMPFC >130 frames (68 patients, 26.7%) had higher clinical and angiographic risk factor profiles as well as a higher 30-day MACE rate compared with those with TMPFC ≤90 frames and those with TMPFC >90 and ≤130 frames. Multivariable analysis identified that the independent predictors of TMPFC >130 frames were age ≥75 years (OR 2.08, 95% CI 1.21 to 3.58, P=0.007), diabetes (OR 1.37, 95% CI 1.01 to 1.86, P=0.042), Killip class ≥2 (OR 1.52, 95% CI 1.05 to 2.21, P=0.027), and prolonged pain-to-balloon time (OR 1.73, 95% CI 1.07 to 2.79, P=0.013). TMPFC >130 frames was identified as the strongest independent predictor of 30-day major adverse cardiac event (MACE) (OR 2.77, 95% CI 1.21 to 6.31, P=0.008), along with age ≥75 years (OR 2.19, 95% CI 1.11 to 4.33, P=0.016), female gender (OR 1.67, 95% CI 1.03 to 2.70, P=0.038), and Killip class ≥2 (OR 1.83, 95% CI 1.07 to 3.14, P=0.021).

Conclusions  STEMI patients with poor myocardial perfusion assessed by TMPFC had higher risk factor profiles. Advanced age, diabetes, higher Killip class, and longer ischemia time were independent predictors of impaired TMPFC after primary percutaneous coronary intervention. These results emphasize that particular attention should be paid on myocardial microvascular reperfusion in STEMI patients with these risk factors.

  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号